BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen J, Hu X, Li Q, Dai W, Cheng X, Huang W, Yu W, Chen M, Guo Y, Yuan G. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Ann Transl Med 2020;8:1187. [PMID: 33241036 DOI: 10.21037/atm-20-6063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Xu J, Gu X, Chen L, Wu Q, Li H, Bai H, Yang J, Qian J. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma. Front Immunol 2021;12:740790. [PMID: 34733279 DOI: 10.3389/fimmu.2021.740790] [Reference Citation Analysis]
2 Dai L, Cai X, Mugaanyi J, Liu Y, Mao S, Lu C, Lu C. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Sci Rep 2021;11:19711. [PMID: 34611195 DOI: 10.1038/s41598-021-98937-2] [Reference Citation Analysis]
3 Duan S, Zhang X, Wang F, Shi Y, Wang J, Zeng X. Coexistence of oral mucous membrane pemphigoid and lichenoid drug reaction: a case of toripalimab-triggered and pembrolizumab-aggravated oral adverse events. Oral Surg Oral Med Oral Pathol Oral Radiol 2021;132:e86-91. [PMID: 34238713 DOI: 10.1016/j.oooo.2021.05.012] [Reference Citation Analysis]
4 Yuan G, Li R, Li Q, Hu X, Ruan J, Fan W, Wang J, Huang W, Zang M, Chen J. Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study. Ann Transl Med 2021;9:1412. [PMID: 34733964 DOI: 10.21037/atm-21-3020] [Reference Citation Analysis]
5 Zarifa A, Kim JW, Lopez-Mattei J, Palaskas N, Iliescu C, Kim PY. Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management. Korean Circ J 2021;51:579-97. [PMID: 34227272 DOI: 10.4070/kcj.2021.0089] [Reference Citation Analysis]
6 Shen Y, Wang H, Wei J, Li W. Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib. Onco Targets Ther 2021;14:5019-26. [PMID: 34675546 DOI: 10.2147/OTT.S332351] [Reference Citation Analysis]